SCHEMBL9077889

SCHEMBL9077889

O=C(O)COC(Cc1ccccc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 2/20 0.62
PPARG P37231 17/20 0.54
PPARA Q07869 15/20 0.54
ACE P12821 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9427716 0.86 SRR (0.50) SRRPPARGPPARA
SCHEMBL30312733 0.84 SRR (0.49) SRRPPARGPPARA
SCHEMBL3781159 0.83 SRR (0.65) SRRPPARGPPARA
SCHEMBL6429518 0.83 SRR (0.65) SRRPPARGPPARA
SCHEMBL10798806 0.83 SRR (0.65) SRRPPARGPPARA
SCHEMBL4993002 0.81 PPARA (0.69) SRRPPARGPPARA
SCHEMBL1670312 0.81 PPARA (0.69) SRRPPARGPPARA
SCHEMBL1932308 0.80 SRR (0.61) SRRPPARGPPARAACE
SCHEMBL5038982 0.79 NPC1 (0.50) SRR
SCHEMBL4298981 0.79 SRR (0.59) SRRPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12343323-B2 Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof SANTOLECAN PHARMACEUTICALS LLC (US) 2025-07-01 US disclosed
US-20210228530-A1 TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF SANTOLECAN PHARMACEUTICALS LLC 2021-07-29 US disclosed
EP-3812376-A1 PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Santolecan Pharmaceuticals LLC (US) 2021-04-28 EP disclosed
WO-2019242691-A1 PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF 圣多利康制药责任有限公司 2019-12-26 WO disclosed
CN-103641925-B Water solublity polysaccharide and the covalency polyacetylene compound of bearing taxanes, its preparation method and medical usage 王晖 2016-08-17 CN disclosed
US-5534529-A Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 1996-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12343323-B2 Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof DDOST, UGT2B17, UGT1A7 SRR 3052/4885PPARG 2227/4885PPARA 966/4885
US-20210228530-A1 TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF DDOST, UGT2B17, UGT1A7 SRR 3052/4885PPARG 2227/4885PPARA 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.